The United States Food and Drug Administration (US FDA) has concluded inspection at Aurobindo Pharma’s Unit VI - B, a Formulation manufacturing facility, situated at Sangareddy District, Telangana. US FDA has conducted inspection from September 22 to September 29, 2023. At the end of the inspection, a ‘Form 483’ was issued with 1 observation which is procedural in nature.
Aurobindo Pharma is engaged in manufacturing pharmaceutical products. It offers active pharmaceutical ingredients, intermediates and generic formulations like astemizole, domeperidone and omeprazole; anti-infective, oral and sterile antibiotics, pain management and osteoporosis segments.
